Genmab
Genmab is a drug therapy company focused on differentiated antibody products in oncology. The company has developed industry-leading antibody discovery technologies which have led to a strong pipeline of potential best-in-class and first-in-class therapies. Through partnerships Genmab has successfully developed several products, including treatments for multiple myeloma, cervical cancer, multiple sclerosis and thyroid eye disease.
Visit their site- Enterprise value
- US$10.8 bn
- Region
- Denmark
- Theme
- Health
- Sub-theme
- Pharmaceutical therapies
Impact Score
Genmab’s therapies are typically used to treat diseases with very poor outcomes where survival rates are measured in months. Their largest drug has shown significant improvements in progression-free survival and remission rates 6x better than the existing treatments. Clinical studies of pipeline drugs also show promising early data.
Fundamental Quality
Genmab’s antibody platform technology is industry-leading. To date it has operated under a partnership model which has allowed it to develop a strong pipeline while generating strong margins and building up a net cash balance sheet. The next stage of growth will see Genmab take a greater share of the economics by participating in the commercialisation stage.
UN SDGs
Genmab’s therapies support SDG 3 in the context of reducing mortality from non-communicable diseases through treatment.
Find out moreRisk of negative impacts
- Side-effects from pharmaceuticals
- Product pricing restricts access for poor communities
- Plastic waste from packaging
- Animal testing of pharmaceuticals
Related insights Related
Sustainable
The next constraint on AI is not just energy, it's also water
By Ty Lee
10 Mar 2026 | 3 min read
Sustainable
From villain to saviour – renewable energy is coming to the rescue
By WHEB Investment Team
17 Feb 2026 | 6 min read
Sustainable
Are EVs really rolling backwards?
By WHEB Investment Team
19 Jan 2026 | 5 min read
Sustainable
Sustainable investment trends for 2026
By Seb Beloe
19 Jan 2026 | 5 min read